raltegravir potassium · Msd Sub Merck · NDA 022145
Isentress Hd
Blocked by patent: US 10772888. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 4 unexpired
6 Orange Book listing rows for 4 patents, including 2 pediatric extensions. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 10772888 | use U-1663 · sets the listed date | 30 Mar 2032 |
| US 9649311 | drug product | 21 Apr 2031 |
| US 9649311 listing row | drug product | 21 Oct 2030 |
| US 9649311 listing row | pediatric extension | 21 Apr 2031 |
| US 8771733 | drug substance, drug product, use U-257 | 2 Jun 2030 |
| US 7754731 | drug substance, drug product, use U-257 | 11 Sep 2029 |
| US 7754731 listing row | drug substance, drug product, use U-257 | 11 Mar 2029 |
| US 7754731 listing row | pediatric extension | 11 Sep 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022145 · 002 · RLD | tablet, oral | EQ 600MG BASE | 30 Mar 2032 |